Latest / The Vox Markets Podcast
2411: Poolbeg Pharma: What US Payers Really Said
Watch on YouTube
Independent US payer research commissioned by Poolbeg Pharma shows strong commercial backing for POLB 001 — a first-in-class preventative for cancer immunotherapy-induced CRS. Chris from Acumentis Global on what payers said, and what it means for the commercial opportunity ahead.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.